The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Strontium-89     strontium

Synonyms: AC1NTUP8, Sr 89, 14158-27-1, 20672-06-4, 31083-24-6, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of strontium


Psychiatry related information on strontium


High impact information on strontium


Chemical compound and disease context of strontium


Biological context of strontium


Anatomical context of strontium

  • The contribution of specific activity to the effects of the bone-seeking isotope, strontium 89 on radiosensitive components of mononuclear phagocyte populations was investigated in mice [19].
  • Platelets and leukocytes fell by an average 30-40% after strontium-89 but sequelae were uncommon, and other symptoms rare [20].
  • In severely monocytopenic mice induced by the administration of strontium-89, Kupffer cells have a proliferative capacity and are maintained by self-renewal [21].
  • B lymphocyte differentiation in lethally irradiated and reconstituted mice. I. The effect of Strontium-89 induced bone marrow aplasia on the recovery of the B cell compartment in the spleen [22].

Associations of strontium with other chemical compounds


Gene context of strontium


Analytical, diagnostic and therapeutic context of strontium


  1. Strontium 89 therapy for the palliation of pain due to osseous metastases. Robinson, R.G., Preston, D.F., Schiefelbein, M., Baxter, K.G. JAMA (1995) [Pubmed]
  2. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. Tu, S.M., Kim, J., Pagliaro, L.C., Vakar-Lopez, F., Wong, F.C., Wen, S., General, R., Podoloff, D.A., Lin, S.H., Logothetis, C.J. J. Clin. Oncol. (2005) [Pubmed]
  3. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. Mertens, W.C., Porter, A.T., Reid, R.H., Powe, J.E. J. Nucl. Med. (1992) [Pubmed]
  4. Kupffer cell proliferation and glucan-induced granuloma formation in mice depleted of blood monocytes by strontium-89. Yamada, M., Naito, M., Takahashi, K. J. Leukoc. Biol. (1990) [Pubmed]
  5. Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89. Edwards, G.K., Santoro, J., Taylor, A. J. Nucl. Med. (1994) [Pubmed]
  6. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Porter, A.T., McEwan, A.J., Powe, J.E., Reid, R., McGowan, D.G., Lukka, H., Sathyanarayana, J.R., Yakemchuk, V.N., Thomas, G.M., Erlich, L.E. Int. J. Radiat. Oncol. Biol. Phys. (1993) [Pubmed]
  7. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Tu, S.M., Millikan, R.E., Mengistu, B., Delpassand, E.S., Amato, R.J., Pagliaro, L.C., Daliani, D., Papandreou, C.N., Smith, T.L., Kim, J., Podoloff, D.A., Logothetis, C.J. Lancet (2001) [Pubmed]
  8. Development, differentiation, and phenotypic heterogeneity of murine tissue macrophages. Naito, M., Umeda, S., Yamamoto, T., Moriyama, H., Umezu, H., Hasegawa, G., Usuda, H., Shultz, L.D., Takahashi, K. J. Leukoc. Biol. (1996) [Pubmed]
  9. The significance of local resident pulmonary alveolar macrophage proliferation to population renewal. Sawyer, R.T. J. Leukoc. Biol. (1986) [Pubmed]
  10. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Porter, A.T., McEwan, A.J. Semin. Oncol. (1993) [Pubmed]
  11. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. Nilsson, S., Strang, P., Ginman, C., Zimmermann, R., Edgren, M., Nordström, B., Ryberg, M., Kälkner, K.M., Westlin, J.E. Journal of pain and symptom management. (2005) [Pubmed]
  12. Irradiation in relapsing carcinoma of the prostate. Perez, C.A., Cosmatos, D., Garcia, D.M., Eisbruch, A., Poulter, C.A. Cancer (1993) [Pubmed]
  13. Neutrophil involvement in effects of diethylstilbestrol and strontium 89 on macrophage activation by Propionibacterium acnes. Ackermann, M.F., Morahan, P.S. Int. J. Immunopharmacol. (1988) [Pubmed]
  14. Radionuclide-targeted therapy for the management of metastatic bone pain. Ackery, D., Yardley, J. Semin. Oncol. (1993) [Pubmed]
  15. Cyclic erythropoiesis in the S1/S1d mouse. Gibson, C.M., Gurney, C.W., Gaston, E.O., Simmons, E.L. Exp. Hematol. (1984) [Pubmed]
  16. Analysis of the participation of N-acetylglucosamine in the different steps of sperm-zona pellucida interaction in hamster. Zitta, K., Wertheimer, E., Miranda, P.V. Mol. Hum. Reprod. (2004) [Pubmed]
  17. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Robinson, R.G., Blake, G.M., Preston, D.F., McEwan, A.J., Spicer, J.A., Martin, N.L., Wegst, A.V., Ackery, D.M. Radiographics : a review publication of the Radiological Society of North America, Inc. (1989) [Pubmed]
  18. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Pagliaro, L.C., Delpassand, E.S., Williams, D., Millikan, R.E., Tu, S.M., Logothetis, C.J. Cancer (2003) [Pubmed]
  19. Selectively eliminated blood monocytes and splenic suppressor macrophages in mice depleted of bone marrow by strontium 89. Shibata, Y., Dempsey, W.L., Morahan, P.S., Volkman, A. J. Leukoc. Biol. (1985) [Pubmed]
  20. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Quilty, P.M., Kirk, D., Bolger, J.J., Dearnaley, D.P., Lewington, V.J., Mason, M.D., Reed, N.S., Russell, J.M., Yardley, J. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. (1994) [Pubmed]
  21. Development, differentiation, and maturation of Kupffer cells. Naito, M., Hasegawa, G., Takahashi, K. Microsc. Res. Tech. (1997) [Pubmed]
  22. B lymphocyte differentiation in lethally irradiated and reconstituted mice. I. The effect of Strontium-89 induced bone marrow aplasia on the recovery of the B cell compartment in the spleen. Rozing, J., Buurman, W.A., Benner, R. Cell. Immunol. (1976) [Pubmed]
  23. Targeted and systemic radiotherapy in the treatment of bone metastasis. Lin, A., Ray, M.E. Cancer Metastasis Rev. (2006) [Pubmed]
  24. Prostate cancer in the late 1990s: hormone refractory disease options. Moul, J.W., Lipo, D.R. Urologic nursing : official journal of the American Urological Association Allied. (1999) [Pubmed]
  25. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Kossman, S.E., Weiss, M.A. Cancer (2000) [Pubmed]
  26. Strontium-89 treatment for prostate cancer bone metastases: does a prostate-specific antigen response predict for improved survival? Zyskowski, A., Lamb, D., Morum, P., Hamilton, D., Johnson, C. Australasian radiology. (2001) [Pubmed]
  27. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Windsor, P.M. Clinical oncology (Royal College of Radiologists (Great Britain)) (2001) [Pubmed]
  28. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Paszkowski, A.L., Hewitt, D.J., Taylor, A. Clinical nuclear medicine. (1999) [Pubmed]
  29. Establishing schedules for repeated doses of strontium and for concurrent chemotherapy in hormone-resistant patients with prostate cancer: measurement of blood and urine strontium levels. Ben-Yosef, R., Pelled, O., Marko, R., Vexler, A., Teshuva, A., German, U., Levita, M., Kol, R. Am. J. Clin. Oncol. (2005) [Pubmed]
  30. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. Breen, S.L., Powe, J.E., Porter, A.T. J. Nucl. Med. (1992) [Pubmed]
  31. The cytokinetic behavior of pulmonary alveolar macrophages in monocytopenic mice. Sawyer, R.T. J. Leukoc. Biol. (1986) [Pubmed]
  32. Strontium-89 therapy for the pain of osseous metastases. Silberstein, E.B., Williams, C. J. Nucl. Med. (1985) [Pubmed]
  33. The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology. Rose, C.M., Kagan, A.R. Int. J. Radiat. Oncol. Biol. Phys. (1998) [Pubmed]
  34. The palliative role of radiotherapy in the management of the cancer patient. Ciezki, J., Macklis, R.M. Semin. Oncol. (1995) [Pubmed]
WikiGenes - Universities